Our Story

Julie joined Brandon Capital in 2022.

Julie M Cherrington, PhD is an experienced life science executive with extensive insight in bringing drugs into the clinic through to commercialisation. She has been a key contributor to the successful development of multiple FDA-approved products, including SUTENT®, PALLADIA®, VISTIDE®, VIREAD®, and HEPSERA®.

Dr. Cherrington is also a successful company builder. She has served as President and Chief Executive Officer at several biotechnology companies, including QUE Oncology, Arch Oncology, Revitope Oncology, Zenith Epigenetics, and Pathway Therapeutics. In addition, she served as President and Executive Vice President, R&D at Phenomix Corporation, a diabetes and antiviral company. Earlier in her career, Dr. Cherrington was Vice President of Preclinical and Clinical Research at SUGEN, a Pharmacia/Pfizer company. Dr. Cherrington began her career at Gilead Sciences, where she held a range of positions of increasing responsibility.

Dr. Cherrington holds a B.S. in biology and an M.S. in microbiology from the University of California, Davis. She received her Ph.D. training in microbiology and immunology from the University of Minnesota and Stanford University and completed a postdoctoral fellowship at the University of California, San Francisco.

Currently, she serves on the Boards of Syncona Ltd, MycRx (chair), Actym Therapeutics (chair), and Tolremo Therapeutics (chair). Additionally, she is an advisor to Janux Therapeutics and TegMine Therapeutics.